Nihon Kohden agreed to acquire 71.4% of NeuroAdvanced Corp., the parent of Ad-Tech Medical Instrument, for an estimated ¥16 billion. Ad-Tech makes intracranial electrodes used for long-term EEG monitoring, brain mapping and stimulation in epilepsy treatment. Investment firm ARCHIMED kept a minority stake as a partner. Why electrodes Nihon Kohden said Ad-Tech's electrodes fit closely with its brain monitoring machines, and that know-how in consumables used for invasive tests and treatment would strengthen its human-machine interface technology. More consumables would also bring steadier, recurring revenue. Buying the rest The minority stake was held by NeuroNewCo, a fund advised by the healthcare investor ARCHIMED. In July 2025 the fund used its right to sell, and Nihon Kohden bought the remaining 28.6% for about ¥7.4 billion, making Ad-Tech wholly owned.
